Exact Sciences Stock Performance
| EXAS Stock | USD 48.67 0.10 0.21% |
EXACT Sciences has a performance score of 4 on a scale of 0 to 100. The firm owns a Beta (Systematic Risk) of 0.76, which means possible diversification benefits within a given portfolio. As returns on the market increase, EXACT Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding EXACT Sciences is expected to be smaller as well. EXACT Sciences now owns a risk of 2.41%. Please confirm EXACT Sciences coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if EXACT Sciences will be following its current price history.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in EXACT Sciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent basic indicators, EXACT Sciences may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return (0.53) | Five Day Return (8.12) | Year To Date Return (14.78) | Ten Year Return 100.88 | All Time Return 223.42 |
1 | Acquisition by James Herriott of 363 shares of EXACT Sciences at 38.26 subject to Rule 16b-3 | 04/30/2025 |
2 | Acquisition by James Herriott of 7334 shares of EXACT Sciences subject to Rule 16b-3 | 05/06/2025 |
3 | Exact Sciences Earns 2025 Great Place To Work Certification | 05/12/2025 |
4 | Exact Sciences Unveils Advanced MRD Test Data for Colorectal Cancer EXAS Stock News | 05/28/2025 |
5 | Disposition of 865 shares by James Herriott of EXACT Sciences subject to Rule 16b-3 | 06/13/2025 |
6 | Raymond James Resumes Coverage of Tectonic Therapeutic With an Outperform Rating | 06/24/2025 |
7 | Forecasting The Future 9 Analyst Projections For Exact Sciences | 07/08/2025 |
8 | Exact Sciences Announces Medicare Coverage for Oncodetect Molec | 07/09/2025 |
9 | Exact Sciences Patent Deemed Unpatentable, Shares Drop EXAS Stock News | 07/10/2025 |
10 | Exact Sciences Corp Announces Q2 2025 Financial Results Release Date EXAS stock news | 07/14/2025 |
11 | Wall Street Analysts Think Exact Sciences Could Surge 26.24 percent Read This Before Placing a Bet | 07/15/2025 |
12 | Grandfield Dodd LLC Has 4.88 Million Stock Position in Exact Sciences Corporation | 07/16/2025 |
13 | Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook - TipRanks | 07/22/2025 |
14 | Incyte Gears Up to Report Q2 Earnings Is a Beat in the Cards | 07/24/2025 |
| Begin Period Cash Flow | 609.7 M | |
| Total Cashflows From Investing Activities | -442.2 M |
EXACT Sciences Relative Risk vs. Return Landscape
If you would invest 4,559 in EXACT Sciences on April 26, 2025 and sell it today you would earn a total of 318.00 from holding EXACT Sciences or generate 6.98% return on investment over 90 days. EXACT Sciences is currently generating 0.137% in daily expected returns and assumes 2.4105% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than EXACT, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
EXACT Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EXACT Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as EXACT Sciences, and traders can use it to determine the average amount a EXACT Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0568
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | EXAS | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.41 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average EXACT Sciences is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EXACT Sciences by adding it to a well-diversified portfolio.
EXACT Sciences Fundamentals Growth
EXACT Stock prices reflect investors' perceptions of the future prospects and financial health of EXACT Sciences, and EXACT Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EXACT Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.0183 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 10.87 B | ||||
| Shares Outstanding | 188.64 M | ||||
| Price To Earning | (38.17) X | ||||
| Price To Book | 3.81 X | ||||
| Price To Sales | 3.25 X | ||||
| Revenue | 2.76 B | ||||
| Gross Profit | 1.97 B | ||||
| EBITDA | (788.73 M) | ||||
| Net Income | (1.03 B) | ||||
| Cash And Equivalents | 728.04 M | ||||
| Cash Per Share | 4.11 X | ||||
| Total Debt | 2.75 B | ||||
| Debt To Equity | 0.77 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 12.71 X | ||||
| Cash Flow From Operations | 210.54 M | ||||
| Earnings Per Share | (5.53) X | ||||
| Market Capitalization | 9.2 B | ||||
| Total Asset | 5.93 B | ||||
| Retained Earnings | (4.5 B) | ||||
| Working Capital | 839.24 M | ||||
| Current Asset | 325.86 M | ||||
| Current Liabilities | 26.72 M | ||||
About EXACT Sciences Performance
Assessing EXACT Sciences' fundamental ratios provides investors with valuable insights into EXACT Sciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the EXACT Sciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 70.55 | 123.41 | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.20) | (0.21) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.43) | (0.45) |
Things to note about EXACT Sciences performance evaluation
Checking the ongoing alerts about EXACT Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for EXACT Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 2.76 B. Net Loss for the year was (1.03 B) with profit before overhead, payroll, taxes, and interest of 1.97 B. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Incyte Gears Up to Report Q2 Earnings Is a Beat in the Cards |
- Analyzing EXACT Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EXACT Sciences' stock is overvalued or undervalued compared to its peers.
- Examining EXACT Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EXACT Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of EXACT Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EXACT Sciences' stock. These opinions can provide insight into EXACT Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.